HANSOH PHARMA(HK:03692) 智通财经网·2026-01-13 03:44Core Viewpoint - Hansoh Pharmaceutical (03692) has seen a stock price increase of over 4%, currently trading at HKD 42.12, following the announcement of a new indication for its innovative drug Amelot (Ametinib Mesylate Tablets) [1] Group 1: Drug Approval and Indications - On January 8, Hansoh Pharmaceutical announced that its innovative drug Amelot received a drug registration certificate from the National Medical Products Administration (NMPA) in China, approving it for use in combination with pemetrexed and platinum-based chemotherapy for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations [1] - This marks the fifth approved indication for Amelot, highlighting the drug's expanding therapeutic applications [1] Group 2: Research Findings - Recent research results published in the prestigious oncology journal Lancet Oncology indicate that Amelot significantly improves disease-free survival (DFS) in patients with completely resected stage II-III B EGFR-mutant NSCLC, demonstrating good safety [1]